110 related articles for article (PubMed ID: 35381768)
1. Stem gene expression in breast tumors during chemotherapy: Connection with the main clinical and morphological factors and the disease outcome.
Ibragimova MK; Tsyganov MM; Deryusheva IV; Slonimskaya EM; Litviakov NV
J Cancer Res Ther; 2022; 18(1):89-95. PubMed ID: 35381768
[TBL] [Abstract][Full Text] [Related]
2. Amplifications of stemness genes and the capacity of breast tumors for metastasis.
Litviakov N; Ibragimova M; Tsyganov M; Kazantseva P; Deryusheva I; Pevzner A; Doroshenko A; Garbukov E; Tarabanovskaya N; Slonimskaya E
Oncotarget; 2020 May; 11(21):1988-2001. PubMed ID: 32523653
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
Prat A; Parker JS; Karginova O; Fan C; Livasy C; Herschkowitz JI; He X; Perou CM
Breast Cancer Res; 2010; 12(5):R68. PubMed ID: 20813035
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
6. Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.
Enomoto Y; Morimoto T; Nishimukai A; Higuchi T; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Nomura T; Takeda M; Watanabe T; Hirota S; Miyoshi Y
Int J Clin Oncol; 2016 Apr; 21(2):254-261. PubMed ID: 26338270
[TBL] [Abstract][Full Text] [Related]
7. Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen.
McFall T; McKnight B; Rosati R; Kim S; Huang Y; Viola-Villegas N; Ratnam M
J Biol Chem; 2018 Jan; 293(4):1163-1177. PubMed ID: 29162724
[TBL] [Abstract][Full Text] [Related]
8. Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer.
Pölcher M; Braun M; Tischitz M; Hamann M; Szeterlak N; Kriegmair A; Brambs C; Becker C; Stoetzer O
Arch Gynecol Obstet; 2021 Sep; 304(3):783-790. PubMed ID: 33585986
[TBL] [Abstract][Full Text] [Related]
9. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
10. Absence of estrogen receptor is associated with worse oncologic outcome in patients who were received neoadjuvant chemotherapy for breast cancer.
Park YR; Lee J; Jung JH; Kim WW; Park CS; Lee RK; Chae YS; Lee SJ; Park JY; Park JY; Park HY
Asian J Surg; 2020 Mar; 43(3):467-475. PubMed ID: 31204155
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes.
Althobiti M; Muftah AA; Aleskandarany MA; Joseph C; Toss MS; Green A; Rakha E
Breast Cancer Res Treat; 2020 Aug; 182(3):581-589. PubMed ID: 32524353
[TBL] [Abstract][Full Text] [Related]
12. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
13. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.
Kim Y; Sim SH; Park B; Lee KS; Chae IH; Park IH; Kwon Y; Jung SY; Lee S; Ko K; Kang HS; Lee CW; Lee ES
Clin Breast Cancer; 2018 Dec; 18(6):459-467.e1. PubMed ID: 29954674
[TBL] [Abstract][Full Text] [Related]
14. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients.
Xu C; Wei Q; Guo J; Zhou JC; Mei J; Jiang ZN; Shen JG; Wang LB
Ann Surg Oncol; 2015; 22(6):2034-9. PubMed ID: 25707489
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.
Al-Saleh K; Salah T; Arafah M; Husain S; Al-Rikabi A; Abd El-Aziz N
PLoS One; 2021; 16(3):e0247802. PubMed ID: 33667252
[TBL] [Abstract][Full Text] [Related]
16. Superior breast cancer metastasis risk stratification using an epithelial-mesenchymal-amoeboid transition gene signature.
Emad A; Ray T; Jensen TW; Parat M; Natrajan R; Sinha S; Ray PS
Breast Cancer Res; 2020 Jul; 22(1):74. PubMed ID: 32641077
[TBL] [Abstract][Full Text] [Related]
17. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
19. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
20. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]